ETA2022 Poster Presentations Nodules & Cancer (10 abstracts)
Neoadjuvant effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
Liang Shi 1 , Qinqin You 1 , Jun Wang 1 , Hanjin Wang 2 , Shaohua Li 1 , Rui Tian 1 , Xiaocheng Yao 1 , Wenyu Wu 1 , Lele Zhang 1 , Feng Wang 1 , Yansong Lin 3 & Shuren LI 4
1Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical Uni-Versity, Nanjing, China; 22. Department of General Surgery, Nanjing First Hospital, Nanjing Medical Univer-Sity, Nanjing, China; 33. Department of Nuclear Medicine, Peking Union Medical College (Pumc) Hospi-Tal, Chinese Academy of Medical Sciences & Pumc, China; 4Medical University of Vienna, Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Vienna, Austria
Purpose: Recently, apatinib, an orally anti-angiogenic tyrosine kinase inhibitor (TKI) is reported to be useful for treatment of progressive RAIR-DIC. The aim of this study was to evaluate the effect of apatinib and the combination therapy with radioactive iodine (RAI) in patients with progressive metastatic DTC.
Methods: Five patients (all female mean age 62 ± 8 years, ranged from 51 to 69 years) with progressive distant metastatic DTC (dmDTC) after total thyroidectomy (TTE) and neck lymph node dissection were treated with apatinib at a dose 500 mg per day after18 F-Fluorodeoxyglucose (18F-FDG) PET/CT. The effects of apatinib on DTC were evaluated at 4 ± 1 months after treatment with apatinib. RAI therapy was then initiated. The response to apatinib and the combination therapy with RAI treatment was evaluated by Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) and metabolic activity using serum thyroglobulin (Tg) and18F-FDG PET/CT.
Results: Positive 18F-FDG PET/CT results were found in all patients before apatinib therapy. The immunohistochemical analysis of primary tumour tissues showed high expression of vascular endothelial growth factor receptor-2 (VEGFR-2). Four patients with follicular thyroid carcinoma (FTC) showed partial response (PR) with significant decrease in tumour size and maximum standardized uptake value (SUVmax) after 4 ± 1 month’s treatment with apatinib. Further significant reduction of tumour size and SUVmax were observed in three patients after combination therapy with apatinib and RAI. Only one patient with both FTC and papillary thyroid cancer (PTC) demonstrated progressive disease (PD) after treatment with apatinib alone, however, a decrease in tumour size and SUVmax as well as serum Tg levels was achieved after the combination with RAI therapy and apatinib.
Conclusions: Apatinib had significant neoadjuvant antitumour effects on progressive distant metastatic DTC. Moreover, beneficial complementary effects were shown when apatinib combined with RAI therapy.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more